Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation and former Novo Nordisk CEO, Lars Rebien Sørensen, is joining the pharma company's board, initially as an observer.